Should I Buy BOLD? BOLD 2026 Analysis

Should You Buy Boundless Bio Inc (BOLD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.160

1 Day change

6.42%

52 Week Range

2.480

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now (avoid / sell). The stock is in a strong downtrend with worsening momentum, and there are no Intellectia buy signals to justify an impatient entry.
Price is already trading below key levels (below Pivot 1.176 and near/below S1 1.066 in pre-market), increasing the odds of further downside toward S2 ~0.997.
No near-term catalysts: no news this week, no notable hedge fund/insider trend, and no congress trading data.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.

Technical Analysis

Trend: Bearish (SMA_200 > SMA_20 > SMA_5), signaling a sustained downtrend across long/medium/short timeframes.
Momentum: MACD histogram -0.0182 and negatively expanding → bearish momentum is strengthening.
RSI (6): 11.515 → extremely oversold; a short bounce is possible, but oversold alone is not a reliable buy trigger in a falling trend.
Key levels: Pivot 1.176 (overhead resistance). Near supports: S1 1.066, then S2 0.997. Pre-market at 1.04 is already pressing the support zone.
Pattern-based outlook: Similar-pattern stats imply negative drift: ~-1.02% (1w), -3.93% (1m) bias.

Positive Catalysts

- Deeply oversold RSI could produce a tactical dead-cat bounce.
- If price reclaims S1 (1.066) and then Pivot (1.176), it would improve the short-term setup (not currently happening pre-market).

Neutral/Negative Catalysts

- Strong bearish trend + worsening MACD suggests downside pressure remains active.
- Pre-market weakness (1.04, -4.59%) keeps the stock pinned near breakdown territory (toward 0.997).
- No fresh news/catalysts this week to shift sentiment.
- Trading positioning signals are neutral (hedge funds/insiders), offering no supportive flow backdrop.

Financial Performance

Latest quarter: 2025/Q3
Revenue: 0 (no YoY growth; essentially pre-revenue).
Net income: -13.879M, down -15.93% YoY (losses widening).
EPS: -0.62, down -16.22% YoY (deteriorating per-share performance).
Overall: financial trend shows continued cash burn / increasing losses with no revenue inflection visible in the snapshot.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target change data was provided, so a Wall Street consensus trend cannot be verified from the dataset.
With the available inputs (downtrend, no catalysts, worsening losses), the practical pro/con skew is more negative than positive until momentum and/or fundamentals improve.

1 Analyst Rating

Wall Street analysts forecast BOLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BOLD is 4 USD with a low forecast of 4 USD and a high forecast of 4 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.090

Low

Averages

High

Current: 1.090

Low

Averages

High

H.C. Wainwright

Buy

downgrade

$5 -> $4

AI Analysis

2025-08-11

Reason

H.C. Wainwright

Price Target

$5 -> $4

AI Analysis

2025-08-11

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Boundless Bio to $4 from $5 and keeps a Buy rating on the shares following the Q2 report.

Goldman Sachs

Richard Law

initiated

2025-07-24

Reason

Goldman Sachs

Richard Law

Price Target

2025-07-24

initiated

Reason

Goldman Sachs analyst Richard Law initiated coverage of Boundless Bio with an Early-Stage Biotech rating, saying the company's combo approach for its lead asset BBI-355 comes with high risk.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BOLD

Unlock Now

BOLD Should I Buy

BOLD Should I Buy

Should You Buy Boundless Bio Inc (BOLD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch